CC-122 immunomodulatory effects in refractory patients with diffuse large B-cell lymphoma.

导出 LinkOut

翻译打印收藏纠错

作者： Carolina,Cubillos-Zapata ^[1] ; Raúl,Cordoba ^[2] ; José,Avendaño-Ortiz ^[3] ; Cristina,Arribas-Jiménez ^[3] ; Enrique,Hernández-Jiménez ^[1] ; Víctor,Toledano ^[1] ; Teresa,Villaescusa ^[2] ; Víctor,Moreno ^[2] ; Eduardo,López-Collazo ^[1]

作者单位： The Innate Immune Response Group, IdiPAZ, La Paz University Hospital, Madrid, Spain; Tumor Immunology Laboratory, IdiPAZ, Madrid, Spain; Center for Biomedical Research Network, CIBEres, Madrid, Spain. ^[1] Lymphoma Unit, Oncohealth Institute, Foundation Jimenez Diaz University Hospital, Health Research Institute IIS-FJS, Autonomous University of Madrid, Madrid, Spain; START Madrid FJD, Phase 1 Clinical Trials Unit, Foundation Jiménez Díaz University Hospital, Madrid, Spain. ^[2] The Innate Immune Response Group, IdiPAZ, La Paz University Hospital, Madrid, Spain; Tumor Immunology Laboratory, IdiPAZ, Madrid, Spain. ^[3]

关键词 CC-122 treatment DLBCL patients immune response

DOI 10.1080/2162402X.2016.1231290

PMID 28255524

发布时间 2021-01-12

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览21

Oncoimmunology

e1231290页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

CC-122 immunomodulatory effects in refractory patients with diffuse large B-cell lymphoma.

Oncoimmunology

相似文献

Oncoimmunology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

CC-122 immunomodulatory effects in refractory patients with diffuse large B-cell lymphoma.

Oncoimmunology

相似文献

Oncoimmunology

相关期刊

检索历史清除